

# **Dewmar International BMC, Inc.**

TIN No. 26-4465583  
State of Incorporation Nevada

**Financial Disclosure Statement for the following reporting periods:**

**Year ended December 31, 2015**

**Year ended December 31, 2016**

**1<sup>st</sup> Quarter ended March 31, 2017**

## General Disclosure Information

### 1) Name of issuer

Dewmar International BMC, Inc.

Address of Principal Executive Offices

132 E. Northside Drive

Suite C

Clinton, MS 39056

Phone: (601) 488-4360

EMAIL: [info@dewmarinternational.com](mailto:info@dewmarinternational.com)

Website: [www.dewmarinternational.com](http://www.dewmarinternational.com)

### 2) Security Information

Trading Symbol: DEWM

### Common Stock

CUSIP: 25211R102

Par or Stated Value: \$ 0 .0001

Total shares authorized: 4,500,000,000 as of: 6/10/17

Total shares outstanding GAAP: 2,814,542,401 as of: 6/10/17

Total shares outstanding non-GAAP: 2,426,163,513 as of: 6/10/17

Total shares authorized: 4,500,000,000 as of: 12/31/16

Total shares outstanding GAAP: 2,814,542,401 as of: 12/31/16

Total shares outstanding non-GAAP: 2,426,163,513 as of 12/31/16

Total shares authorized: 4,500,000,000 as of: 12/31/15

Total shares outstanding GAAP: 2,814,542,401 as of: 12/31/15

Total shares outstanding non-GAAP: 2,426,163,513 as of: 12/31/15

### Preferred Stock

Par or Stated Value: \$0.001

Total Shares Authorized: 50,000,000 as of: 6/10/17

Total shares outstanding: 50,000,000 as of: 6/10/17

Total Shares Authorized: 50,000,000 as of: 12/31/16

Total shares outstanding: 50,000,000 as of: 12/31/16

Total Shares Authorized: 50,000,000 as of: 12/31/15

Total shares outstanding: 50,000,000 as of: 12/31/15

List any trading suspensions: **NONE**

Total public float: 2,256,863,590 as of 06/10/17

### 3) Financial Statements

Following this section on General Disclosure Information are the Balance Sheets as of December 31, 2015 and 2016, the Statement of Operations and Statements of Cash Flows for the years then ended. The same set of documents is provided for the 1<sup>st</sup> quarter period of 2017 ended on March 31.

### 4) Describe the Issuer's Business, Products and Services

**A. Business Operations:** Dewmar International BMC, Inc. is a diversified operating company headquartered in Clinton, Mississippi with additional office locations in New Orleans, Louisiana; Houston, Texas and Denver, Colorado. The Company conducts business across a variegated set of categories and sectors including consumer goods, wholesale trade, pharmaceuticals and health sciences. The company and its subsidiaries develops, markets and distributes goods, therapeutics and a host of professional services across national and international markets through licensing agreements, distribution contracts, fee-for-service arrangements and e-commerce platforms.

#### Health Wellness Research Consortium (HWRC)

On December 4, 2014 Health & Wellness Research Consortium, LLC, was created with Dewmar owning 100% of the LLC membership units.

The original goal was to develop, implement and execute healthcare sales and marketing strategies for pharmacies, clinics and hospitals to help the client broaden market presence, influence effective prescribing behaviors and ultimately maximize their return on assets. HWRC is a contract sales and marketing organization of its own; created to leverage the trend toward outsourcing services in the healthcare industry. Through a network of medical facilities, doctors, pharmacies and patients, HWRC develops innovative solutions that utilize delivery gaps in health care such as mail-order delivery of prescription medicine to rural areas where limited options exist for specialty prescription medication and telehealth service options.

In this function, HWRC will typically enter into a fee-for-service arrangement with a medical service provider organization to assist them with their sales and marketing functions. Under the fee-for-service construct, HWRC is able to realize high margin revenue associated with the delivery of care, without being saddled with the burdensome administrative and overhead costs absorbed by the provider.

The timing was perfect as the healthcare industry is going through significant change and a paradigm shift that allows us to exploit market opportunities that larger, less nimble companies overlook. By leveraging our unique combination of R&D expertise, understanding of the healthcare landscape, marketing capabilities and the relationships we have in the industry, HWRC is able to deliver quick and measurable value-add to the bottom line of our clients and the quality of care to their patients.

To optimize revenue and profit potential for the company, HWRC contracts services under a revenue share model. As reflected in the financials posted in our most recent 8K filing, this has generated millions in sustained revenue for the business. Furthermore, HWRC has established a fund to invest in healthcare technologies, real property, innovative practices and diagnostic equipment. We provide our partners and clients with the unique insight to improve their performance and achieve sustained profitable growth.

#### Brand Management Company (BMC)

The Brand Management Company division, which is the BMC portion of Dewmar International BMC, Inc., is a leading provider of consumer brands to global markets. The Company's primary business strategy has been the creation, manufacturing, marketing and distribution of its select portfolio of innovative consumer products through established distribution channels inclusive of national and international retailers. BMC's primary source of revenue is through the wholesale of its branded products.

Dewmar's portfolio of consumer brands includes Company-owned and trademarked brands as well as those brands obtained through license and distribution agreements with partner brand owners.

**B. Date and State of Incorporation:** November 11, 2009 in Nevada

**C. The issuer's primary and secondary SIC Codes:**

Primary: 8741

Secondary: 8099; 5912, 5149, 7999, 5812

**D. The issuer's fiscal year end date:** December 31

**E. Principal products or services, and their markets:**

Healthcare, Beverages, Consumer Goods, Brand Management, Cannabis and Entertainment.

**5) Describe the Issuer's Operations and Facilities**

- A. Manufacturer, wholesaler and marketer of edible relaxation products
- B. Owner and operator of medical facilities, pharmacies and wellness clinics
- C. Brand manager of owned and licensed Consumer Goods sold at big box retailers
- D. Restaurant owner of fast casual dining concept in West Monroe, Louisiana
- E. Executive producer of entertainment media content and documentaries

Issuers executive offices are located at:

132 E. Northside Drive  
Suite C  
Clinton, MS 39056

**6) Officers, Directors, and Control Persons**

**A. Names of Officers, Directors, and Control Persons**

Name	Position with the Company	Term Of Office
Dr. Marco Moran	Director, CEO, Treas, CFO	September 2009 to Present
J.D. Houston	Director, President & COO	May 1, 2014 to Present
Derrick Brooks	Director	March 19, 2012 to Present

**B. Legal/Disciplinary History**

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses): **NONE**
2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities: **NONE**
3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated: **NONE**

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities: **NONE**

C. Beneficial Shareholders

Dr. Marco Moran holds 100% of Series A Preferred Stock -thus having voting control over the corporation.

**7) Issuer Certification**

I, Dr. Marco Moran certify that:

1. I have reviewed this Disclosure Statement Report of Dewmar International BMC, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

**June 15, 2017**



**Marco Moran**

**Chief Executive Officer**

**UNAUDITED FINANCIAL STATEMENTS FOR THE YEARS ENDED  
DECEMBER 31, 2016 AND DECEMBER 31, 2015**

DEWMAR INTERNATIONAL BMC, INC.			
UNAUDITED CONSOLIDATED BALANCE SHEETS			
		December 31,	December 31,
		2016	2015
<b>ASSETS</b>			
Current assets:			
Cash and cash equivalents	\$	180,704	\$ 1,989,797
Accounts receivable		136,391	68,099
Notes receivable		3,301,077	2,449,223
Inventory		154,956	111,016
Prepaid expenses and other current assets		52,392	45,333
Total current assets		3,825,520	4,663,467
Property and equipment, net			
		304,794	42,645
Other assets		192,761	44,859
Total assets	\$	4,323,076	\$ 4,750,971
<b>LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</b>			
Current liabilities:			
Accounts payable and accrued expenses	\$	924,164	\$ 814,081
Accrued interest		16,053	16,053
Accrued interest, related party		252	252
Notes payable		773,891	393,891
Notes payable, related party		410,150	250,150
Convertible notes		154,320	154,320
Derivative liability		281,706	281,706
Total current liabilities		2,560,535	1,910,453
Total liabilities		2,560,535	1,910,453
<b>STOCKHOLDERS EQUITY (DEFICIT)</b>			
Preferred Stock; \$0.001 par value 50,000,000 shares authorized; 50,000,000 shares issued and outstanding, respectively		50,000	50,000
Common stock; \$0.001 par value; 4,450,000,000 shares authorized; 2,814,542,401 and 2,814,542,401 shares issued and outstanding		2,814,546	2,814,546
Additional paid in capital		4,419,763	4,419,763
Accumulated deficit		(5,521,768)	(4,443,791)
Total Stockholders' Equity		1,762,541	2,840,518
Total Liabilities and Stockholders' Equity	\$	4,323,076	\$ 4,750,971

DEWMAR INTERNATIONAL BMC, INC.					
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS					
				Year Ended December 31,	Year Ended December 31,
				2016	2015
Product revenue, net				\$ 630,800	\$ 415,393
Commission revenue, net				-	2,947,643
Total revenue				630,800	3,363,035
Cost of goods sold				227,776	1,680,615
Gross margin				403,024	1,682,421
Operating expenses:					
Occupancy and related expenses				53,288	38,724
Marketing and advertising				3,091	8,255
General and administrative expenses				1,497,808	1,181,989
Contract labor				47,000	36,617
Total operating expenses				1,601,187	1,265,585
Income(loss) from operations				(1,198,163)	416,836
Other income (expenses):					
Other income				120,184	14,328
Interest expense, net				-	223
Total other income and expense				120,184	14,551
Income(loss) from operations				(1,077,978)	431,387
Provision for income taxes				-	-
<b>Net income (loss)</b>				<b>\$ (1,077,978)</b>	<b>\$ 431,387</b>
Net income loss per fully diluted share				<b>\$ (0.00)</b>	<b>\$ 0.00</b>
Weighted-average number of common shares outstanding:					
Basic and diluted				2,814,542,401	2,814,542,401



DEWMAR INTERNATIONAL BMC, INC.						
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS						
					Year Ended December 31, 2016	Year Ended December 31, 2015
Cash flows from operating activities						
Net income (loss)					\$ (1,077,978)	\$ 431,387
Adjustments to reconcile net loss to cash used in operating activities:						
Depreciation expense					7,550	7,550
Changes in operating assets and liabilities:						
Accounts receivable					(68,292)	10,508
Inventory					(43,940)	(84,943)
Notes receivable					(851,854)	(2,420,590)
Prepays					(7,059)	(45,333)
Other assets					(147,902)	(25,081)
Accounts payable and accrued expenses					110,083	110,256
Accrued interest, related party					-	(2,248)
Net cash provided by (used in) operating activities					(2,079,393)	(2,018,493)
Cash flows from investing activities:						
Acquisition of capital assets					(269,700)	(30,900)
Net cash provided by (used in) financing activities					(269,700)	(30,900)
Cash flows from financing activities:						
Proceeds from the issuance notes payable					380,000	220,001
Proceeds from the issuance notes payable -related parties					160,000	150,150
Net cash provided by (used in) financing activities					540,000	370,151
Net increase (decrease) in cash and cash equivalents						
Cash and cash equivalents at beginning of period					1,989,797	3,669,039
Cash and cash equivalents at end of period					\$ 180,704	\$ 1,989,797
Supplemental disclosure of cash flow information:						
Cash paid for interest					\$ -	\$ -
Cash paid for income taxes					\$ -	\$ -

**UNAUDITED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED  
MARCH 31, 2017**

<b>DEWMAR INTERNATIONAL BMC, INC.</b>			
<b>UNAUDITED CONSOLIDATED BALANCE SHEETS</b>			
		<b>March 31,</b>	<b>December 31,</b>
		<b>2017</b>	<b>2016</b>
<b>ASSETS</b>			
Current assets:			
Cash and cash equivalents	\$	130,858	\$ 180,704
Accounts receivable		204,654	136,391
Notes receivable		3,308,077	3,301,077
Inventory		169,758	154,956
Prepaid expenses and other current assets		52,392	52,392
Total current assets		3,865,739	3,825,520
Property and equipment, net		302,907	304,794
Other assets		217,231	192,761
Total assets	\$	4,385,877	\$ 4,323,076
<b>LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</b>			
Current liabilities:			
Accounts payable and accrued expenses		975,417	\$ 924,164
Accrued interest		16,053	16,053
Accrued interest, related party		252	252
Notes payable		773,891	773,891
Notes payable, related party		410,150	410,150
Convertible notes		154,320	154,320
Derivative liability		281,706	281,706
Total current liabilities		2,611,788	2,560,535
Total liabilities		2,611,788	2,560,535
<b>STOCKHOLDERS EQUITY (DEFICIT)</b>			
Preferred Stock; \$0.001 par value 50,000,000 shares authorized; 50,000,000 shares issued and outstanding, respectively		50,000	50,000
Common stock; \$0.001 par value; 4,450,000,000 shares authorized; 2,814,542,401 and 2,814,542,401 shares issued and outstanding		2,814,546	2,814,546
Additional paid in capital		4,419,763	4,419,763
Accumulated deficit		(5,510,221)	(5,521,768)
Total Stockholders' Equity		1,774,088	1,762,541
Total Liabilities and Stockholders' Equity	\$	4,385,877	\$ 4,323,076

UNAUDITED CONSOLIDATED STATEMENT OF OPERATIONS				
				For the Three Months Ended March 31, 2017
Product revenue, net				\$ 210,125
Commission revenue, net				-
Total revenue				210,125
Cost of goods sold				49,564
Gross margin				160,561
Operating expenses:				
Occupancy and related expenses				10,510
General and administrative expenses				129,375
Contract labor				22,750
Total operating expenses				162,635
Income(loss) from operations				(2,074)
Other income (expenses):				
Other income				13,621
Interest expense, net				-
Total other income and expense				13,621
Income(loss) from operations				11,547
Provision for income taxes				-
Net income (loss)				\$ 11,547
Net income loss per fully diluted share				\$ 0.00
Weighted-average number of common shares outstanding:				
Basic and diluted				2,814,542,401

DEWMAR INTERNATIONAL BMC, INC.					
UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS					
					For the Three Months Ended
					2017
Cash flows from operating activities:					
Net income (loss)					\$ 11,547
Adjustments to reconcile net loss to cash used in operating activities:					
Depreciation expense					1,888
Changes in operating assets and liabilities:					
Accounts receivable					(68,261)
Inventory					(14,802)
Notes receivable					(7,000)
Prepays					
Other assets					(24,471)
Accounts payable and accrued expenses					51,253
Accrued interest, related party					-
Net cash provided by (used in) operating activities					(49,846)
Cash flows from investing activities:					
Acquisition of capital assets					-
Net cash provided by (used in) financing activities					
Cash flows from financing activities:					
Proceeds from the issuance notes payable					-
Proceeds from the issuance notes payable -related parties					-
Net cash provided by (used in) financing activities					
Net increase (decrease) in cash and cash equivalents					
Cash and cash equivalents at beginning of period					\$ 180,704
Cash and cash equivalents at end of period					\$ 130,858
Supplemental disclosure of cash flow information:					
Cash paid for interest					\$ -
Cash paid for income taxes					\$ -

# NOTES TO THE FINANCIAL STATEMENTS

## NOTE 1: ORGANIZATION AND MANAGEMENT'S PLANS

With the expanded placement of our branded products in Walmart, we continue to see growth in our traditional business lines of brand management and consumer goods. Simultaneously, we are diversifying into new markets and business opportunities that show high growth potential and leverage our expertise in pharmaceuticals, healthcare and product development. A key initiative is in the cannabis market, which is growing rapidly due to legalization and adoption of products for medicinal, nutraceutical and recreational use.

- We are expanding on the initial success of *Kush Cakes*, by improving upon our hemp protein infusion techniques and shelf-life stabilization through improved packaging methods. We have expanded our partnership with bakeries to multiple states that have legal edible cannabis laws.
- We formed U.S. Hemp Corporation to develop consumer products for food, beverage, nutraceutical and medicinal applications, and establish partnerships and brand alliances to promote our products and the industry in general.
- We are in the product development stage of creating well branded edible THC/CBD infused products in multiple states with both medical and recreational cannabis laws. These products are unique in the marketplace and offer a compelling option for Millennials and Generation-X seeking a trusted source of functional products that induce relaxation because not only does it include quality measurements of active CBD, THC, CBDA and THCA; the products may include a host of other synergistic pharmaceutical grade products formulated by our CEO and chief pharmacist.
- We are also developing a list of quality suppliers of Cannabidiol (CBD), a cannabis extract we view as a key ingredient for a wide range of new products which makes for an appealing option for patients looking for relief from inflammation, pain, anxiety, psychosis, seizures, spasms and other conditions without disconcerting feelings of lethargy or dysphoria.
- In addition to product marketing, we provide an array of hemp industry services —with our exclusive *Hemp Incubator* —to foster overall market growth, as well as promote our brands as well as various clients who sign a contract with us. Our services include:
  - Go-to-market consulting and research
  - Brand management
  - Product development and food science testing
  - Third-party manufacturing relationships
  - Warehousing and order fulfillment
- We have also diversified our hemp/cannabis business with other activities to communicate and promote the benefits of the plant. We see these activities as potential revenue contributors, as well as brand-building exercises.
  - We formed a Historically Black Colleges & Universities (HBCU) program for Hemp and Medicinal Cannabis Research, which shall provide a self-directed learning curriculum, including expert lectures on the legal, agricultural, social and business aspects of the hemp/cannabis industry.
  - We are developing partnerships with Colleges and Universities across the globe to study hemp plant cultivation and consumer and industrial applications. We have gained access to over 100 patented technologies in bio-sciences and engineering to aide us in our advancement to develop and introduce new technologies to consumer markets worldwide.
  - We are executive producers of and have extensive product placement in a documentary film, called “Weed for Warriors” which tells the story of how medicinal marijuana, in lieu of harsh sedative pharmaceutical drugs, have helped many disabled veterans cope with their debilitating injuries and post-traumatic stress disorder (PTSD).
  - We have invested in ownership rights and our CEO has a repetitive co-starring role as a panelist, healthcare subject matter specialist and accredited investor in a cannabis business investment reality television series geared toward offering advice and direct cash investments to aspiring “ganja-preneurs” across the United States. This production gives Dewmar the opportunity to find, invest in or acquire the latest cannabis technologies before

they become widespread public knowledge. This series connects Dewmar to a number of celebrity personalities and top industry financial leaders, hedge fund managers and more.

- We have entered into multiple relationships with hemp/cannabis industry leaders.
  - ❖ Minority Cannabis Business Association
    - Marijuana Consumer Awareness
    - Cannabis Patient Advocacy
  - ❖ Mjardin
    - Facilities management
    - Cultivation grow expertise

## **NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

### Basis of Presentation and Principles of Consolidation

The consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. The consolidated financial statements include the accounts of the Company Dewmar International Brand Management Company, Inc. and Health & Wellness Research Consortium, LLC (HWRC). All material intercompany accounts and transactions have been eliminated. Certain amounts in prior periods have been reclassified to conform to current period presentation.

### Cash and Cash Equivalents

Cash and cash equivalents consist primarily of cash on deposit and money market accounts, which are readily convertible into cash and purchased with original maturities of three months or less. These investments are carried at cost, which approximates fair value.

### Investments

Investments in associated companies or ventures are initially recognized at cost, less any provision for impairment. The Company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable. If any such indication of impairment exists, the Company makes an estimate of the recoverable amount. If the recoverable amount of the cash-generating unit is less than the value of the investment, the investment is considered to be impaired and is adjusted to its recoverable amount. An impairment loss is recognized immediately in the profit and loss account.

### Cost of Goods Sold

The Company's cost of goods sold includes all costs of beverage production, which primarily consist of raw materials such as concentrate, sugar, aluminum cans, trays, shrink wrap, can ends, labels and packaging materials. Additionally, costs incurred for shipping, handling and warehousing charges are included in cost of goods sold. The Company does not bill customers for cost of shipping unless the Company incurs additional charges such as refusing initial shipment or not being able to receive shipment at their prescheduled time with the freight company.

### Share-Based Compensation

The Company recognizes all share-based payments to employees, including grants of Company stock options to Company employees, as well as other equity-based compensation arrangements, in the financial statements based on the grant date fair value of the awards. Compensation expense is generally recognized over the vesting period. During the years ended December 31, 2014 and 2013, the Company issued no stock options to employees.

### Concentration of Risks

The Company's operations and future business model are dependent in a large part on the Company's ability to execute its business model. The Company's inability to meet its sales objectives may have a material adverse effect on the Company's financial condition.

### Revenue Recognition Policy

The Company recognizes revenue from two primary sources, sales of product and commissions from HWRC.

The Company recognizes revenue when a 3rd party confirms receipt of any inbound prescriptions from any registered practitioner that has been referred by HWRC and said prescription has been adjudicated and approved by a third party payer to yield a profit. HWRC is allowed to access this secure, password protected portal for prescription verification and for verification of the total adjudication reimbursement amount and cost of the medication. HWRC receives 50% of the gross profit of all adjudicated prescriptions with the exception of government funded third party plans. Our particular commissions earning model keeps HWRC free from any implications of anti-kickback, fraud allegations or Stark Law violations. Revenue is recognized upon confirmation from the third party of the amount of commission and when cash is received.

The Company recognizes product revenue when the product is received by and title passes to the customer. The Company's standard terms are 'FOB' destination. If a customer receives any product that they consider damaged or unacceptable, the customer must document any such damages or reasons for it not to be accepted on the original invoice upon delivery and then inform the Company within 72 hours of receipt of the product. The Company does not accept returns of product for reasons other than damage.

We record estimates for reductions to revenue for customer programs and incentives, including price discounts, volume-based incentives, and promotions and advertising allowances. Products are sold with extended payment terms not to exceed 120 days. Revenue is shown net of sales allowances on the accompanying statements of operations.

### **NOTE 3: Leadership**

The following paragraphs set forth brief biographical information for company leadership:

#### **Marco Moran, CEO, Secretary, CFO, Treasurer, Director, Chief Accounting Officer**

As Chief Executive Officer Marco Moran has overall responsibility for the Company's performance, developing its strategic plan to advance its mission and to manage shareholders' value through profitable revenue growth.

As a licensed Doctor of Pharmacy and graduate degree in Pharmaceutical Sciences, Dr. Moran has direct oversight of all the company's research and development, quality control and product innovation activity.

Dr. Moran served at the U.S. Naval Hospital in Camp Lejeune, North Carolina as a Medical Service Corp Officer and Pharmacist.

Dr. Moran began his private sector career as the Director of Pharmacy and Regulatory Affairs for INO Therapeutics, Inc. in Port Allen, Louisiana where this foreign-owned entity developed the country's first FDA approved pharmaceutical gas, inhaled nitrous oxide (INO), for the treatment of lung development for pre-mature newborns. Dr. Moran's further research in the U.S. and France involved the implication of INO as a gaseous inhalation spray to instantaneously reverse male erectile dysfunction. He has been the pharmacist of record for leading medical providers such as the Mississippi Baptist Health System, River Region Medical Center, Accredo Health, and several retail pharmacy chains. During his time with River Region Medical Center, Dr. Moran managed Six Sigma project teams to assist administration in meeting quality control standards in both the emergency room and operating room settings in order to reduce costs and improve profitability for the entire hospital system.

In 2008, Dr. Moran launched Unique Beverage Group, LLC, where he developed, and marketed his first mix of branded, functional beverages. Dr. Moran single-handedly introduced relaxation beverages to major beer distributors in the deep Southern United States after creating a large network of jobbers and small distributors after training them with guerilla-style marketing tactics. The success of these initial products and the relationships formed during this period eventually lead to the development of Lean Slow Motion Potion and the creation of Dewmar International BMC, Inc.



#### *Education:*

Dr. Moran completed his pre-pharmacy studies at Southern University and Louisiana State University in Baton Rouge, Louisiana. Dr. Moran earned his professional Pharmacy degree, Masters of Business Administration (MBA) with a specialty in Healthcare Administration and Pharmaceutical Sciences postgraduate degrees from the University of Louisiana at Monroe. He further participated in special advanced graduate Marketing studies at the University of South Alabama's esteemed Mitchell College of Business and in participated in advanced post-graduate Accounting Principles at Louisiana Tech University.

Dr. Moran has expanded his pharmaceutical formulation experience by completing basic and advanced training at Professional Compounding Centers of America (PCCA) Compounding in Houston, TX; as a trained American Colleges of the Apothecaries Compounding Specialist in Memphis, TN and has completed numerous specialty courses with the National Community Pharmacists Association.

Dr. Moran has completed various extensive training in New York and California through BevNet Live Entrepreneur School annually since 2009, inclusive of branding, packaging, and entrepreneur coursework to enhance his knowledge of the beverage industry. Additionally, he completed advanced packaging solutions, particularly with aluminum cans, at Ball Corporation headquarters in Broomfield, Colorado.

#### *Public Service:*

Dr. Moran was invited to be an active member of the White House Business Council via the White House Business Forward during the President Obama administration and continues to maintain his position during President Trump's administration. He was appointed Chair of the Mississippi District Export Council which is a position appointed by the United States Department of Commerce and United States Export Assistance Council for a 4 year term. Dr. Moran recently was appointed to a 6 year term of the Executive Committee at Louisiana State University's College of Science.

#### **Jacob Dillon Houston, President and Chief Operating Officer**

On May 1, 2014 we entered into a 3 year employment agreement with Mr. Houston. Under the terms of the agreement, Mr. Houston will receive compensation in the form of a basic salary of \$25,000 per year and additional stock based compensation to be determined at a later date, but not less than 50% of the amount that the CEO receives for compensation of his services.

As President and COO, J.D. Houston has responsibility for revenue management and optimization, operational cost containment and capital raises to fund business growth.

Mr. Houston started his career with IBM Global Financing; first as a portfolio manager of end-of-lease technology assets, then as a Global Trader in Asset Services. In just his third year with IBM, he received an "outperform" review; a designation reserved for the elite Top 1% performers company-wide.

Later in his career, he coupled his corporate success and finance experience to help entrepreneurs increase revenue and accelerate growth. Mr. Houston has held various senior management and Sales leadership roles within target companies.

Noteworthy is Mr. Houston's past involvement with I.D. Systems, Inc. which generated significant revenue growth during his tenure as the Director of Sales, North America. Between the years of 2000-2006, the company grew revenue 1,354%; culminating in March 2006 with the Company's secondary public offering of \$60 million in capital and a top ranking on Deloitte's prestigious "Fast 500" list in 2005 and 2006, respectively.

Mr. Houston, a scholar athlete, graduated with honors from South Carolina State University with a Bachelor of Science degree in Business and holds an MBA from the School of Business & Industry at Florida A&M University.

Past and present honors and certifications include Series 7 Securities license, FINRA Registered Rep., and coveted participation in the opening ceremonies of the NASDAQ Stock Exchange.

Mr. Houston currently holds or has held a seat on The Board of Directors/Trustees for the following organizations:

- The HP Educational Trust
- The IBM Black Executive Task Force

#### **Dr. Derrick Brooks, Director**

Derrick D. Brooks, Sr., M.D., age 42, is a medical physician whose primary role is to serve as a licensed healthcare professional and medical liaison to assist the company in reviewing opportunities in developing new products that assist in mood enhancement, improving functionality and to serve as an additional medical expert as it relates to numerous uses of medicinal cannabis to treat patient populations nationwide.

#### **PROFESSIONAL EXPERIENCE**

Staff Emergency Room Physician (Level II)  
Our Lady of the Lake Regional Medical Center  
July 2003 - April 2011

Staff Emergency Room Physician (Level II)  
Ochsner Baton Rouge  
March 2011 - present

Staff Emergency Room Physician (Level II)  
University Medical Center - Lafayette  
March 2011 - present

Staff Emergency Room Physician (Level III)  
Iberia Medical Center – Iberia  
June 2011 - present

#### **MEDICAL EDUCATION**

Louisiana State University School of Medicine  
Doctor of Medicine 1999  
New Orleans, Louisiana

#### **BOARD CERTIFICATIONS**

American Board of Internal Medicine Certified 2003  
American Board of Pediatrics  
Certified 2003